Evidence map›Paper›PMID 40498591›Full record

ArticleChemical biology & drug design2025

Targeting Cancer Cell Proliferation Using Piperazine-Linked Quinolinequinones: Mechanism and Metabolic Profile.

Ayse Mine Yilmaz, Ayse Tarbin Jannuzzi, Abanish Biswas, Subodh Mondal, Vinay N Basavanakatti, Hatice Yıldırım, Mahmut Yıldız, Nilüfer Bayrak, Venkatesan Jayaprakash, Amaç Fatih TuYuN

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical biology & drug design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ayse Mine YilmazDepartment of Biochemistry, School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0003-0802-523X
Ayse Tarbin JannuzziDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0003-0578-6893
Abanish BiswasDepartment of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Ranchi, Jharkhand, India.
Subodh MondalBioanalysis, Eurofins Advinus BioPharma Services India Pvt Ltd., Bengaluru, Karnataka, India.
Vinay N BasavanakattiAdgyl Lifesciences Private Limited, Bengaluru, Karnataka, India.
Hatice YıldırımDepartment of Chemistry, Engineering Faculty, Istanbul University-Cerrahpasa, Istanbul, Türkiye.ORCID https://orcid.org/0000-0003-3988-6120
Mahmut YıldızDepartment of Chemistry, Gebze Technical University, Kocaeli, Türkiye.
Nilüfer BayrakDepartment of Chemistry, Faculty of Science, Istanbul University, Istanbul, Türkiye.
Venkatesan JayaprakashDepartment of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Ranchi, Jharkhand, India.
Amaç Fatih TuYuNDepartment of Chemistry, Faculty of Science, Istanbul University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0001-5698-1109

Funding

Indian Council of Medical Research IIRP-2023-1052
6 · The paper itself

Abstract

A series of aminated quinolinequinones linked to piperazine analogs (QQ1-7) were synthesized and screened against the full panel of National Cancer Institute (NCI) cancer cell lines for their potential as cytotoxic agents. The Developmental Therapeutics Program of the NCI analyzed the NCI-60 screening results and revealed that seven QQs were potent inhibitors of cancer cell growth across several cell lines, advancing them to the five-dose assay. Encouraged by the NCI five-dose assay results, the cytotoxicity of the selected QQs (QQ1 and QQ4) was further studied in three cancer cell lines-HCT-116 (colon cancer), ACHN (renal cancer), MCF7, and T-47D (breast cancer)-as well as in a normal cell line (HUVEC) for a deeper understanding. QQ1 was the hit compound for ACHN cells with an IC

Indexed as

Antineoplastic AgentsPiperazinesQuinolinesAnimalsApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMaleMicrosomes, LiverMolecular Docking SimulationOxidative StressPiperazineRatsRats, Sprague-DawleyAntineoplastic AgentsPiperazinePiperazinesQuinolinesADMEbreast cancercolon cancercytotoxicitymolecular dynamicsrenal cancer

Identifiers

PMID40498591
PMCPMC12155089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.